Update shared on31 Jul 2025
With no significant changes in either the Discount Rate or Future P/E ratio, Gentherm’s consensus analyst price target remains steady at $42.60.
What's in the News
- Gentherm raised full-year 2025 product revenue guidance to $1.43–$1.5 billion, up from $1.4–$1.5 billion.
- Completed buyback of 1,021,070 shares (3.29% outstanding) for $39.9 million, including 381,600 shares repurchased in the latest tranche for $10.02 million.
- Added to multiple Russell value indexes (Russell 2000 Value, 2500 Value, 3000 Value, 3000E Value, Small Cap Comp Value) and dropped from corresponding growth indexes.
- Expanded partnership with DUOMED into France, enabling wider distribution of patient temperature management products across France and Benelux.
Valuation Changes
Summary of Valuation Changes for Gentherm
- The Consensus Analyst Price Target remained effectively unchanged, at $42.60.
- The Discount Rate for Gentherm remained effectively unchanged, moving only marginally from 7.73% to 7.74%.
- The Future P/E for Gentherm remained effectively unchanged, at 11.31x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.